Craig Thompson, MD, Director, Abramson Cancer Center, moderates press conference on emerging treatments in pancreatic cancer

November 18, 2009

( -- Pancreatic cancer remains one of the deadliest and hardest to treat cancers. After diagnosis, patients tend to live only six months and less than 5 percent survive to five years.

“In terms of a patient population, there is very little we can do for them once we find the cancer,” said Craig Thompson, M.D., director of the Abramson Cancer Center at the University of Pennsylvania.

The currently available treatment is gemcitabine, which is sold as Gemzar by Eli Lilly and Company, but the response rate with this treatment is typically only 5 percent. Researchers are working to develop new ways of treating pancreatic cancer and early scientific studies are showing promise... Read More